Compare AbbVie Inc (ABBV) vs Ulta Beauty Inc (ULTA) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

ULTA stock trades at $565.15, up 4.89% in the last session, with a bullish technical outlook supported by moving averages and strong support at $547. The company reported Q1 2026 EPS of $7.74, beating estimates, but faces margin compression with net income margin declining to 10.63% in 2025. Recent news highlights the end of its Target partnership as a potential growth opportunity, per BofA analysis on July 29, 2026.

The stock offers upside to the consensus price target of $618.29, with 57% of analysts rating it a buy, but risks include competitive pressures and volatile cash flows, with net cash flow turning negative in 2025. Investors should weigh robust ROE of 47.45% against elevated P/B of 9.41 and RSI levels suggesting overbought conditions.